A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents

Trial Profile

A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Fluticasone furoate (Primary) ; Vilanterol/fluticasone furoate (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 May 2017 Results of a post-hoc analysis from NCT01165138, NCT01686633 and NCT01134042 trials presented at the 113th International Conference of the American Thoracic Society
    • 06 Dec 2013 Primary endpoint `superiority of vilanterol/fluticasone furoate 100/25 mcg vs fluticasone furoate in 0-24 hour weighted mean forced expiratory volume in one second (FEV1)' has been met, according to a Theravance media release.
    • 06 Dec 2013 Data from this trial will support a potential filing for vilanterol/fluticasone furoate for the treatment of asthma in adults in the USA, according to a Theravance media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top